Drug intelligence / Profile preview

GI-101A

Development stage: Phase 2
Lead developer: GI Innovation
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

GI-101A is a bi-specific fusion protein containing the CD80 ectodomain and an interleukin-2 (IL-2) variant, linked via a human immunoglobulin G4 (IgG4) Fc region. It is designed to modulate immune responses by inhibiting CTLA4 through CD80 and enhancing immune cell activation via IL-2. GI-101A is being developed for various cancers, including bladder, Merkel cell, cervical, colorectal, esophageal, head and neck, melanoma, non-small-cell lung, renal cell carcinoma, sarcoma, squamous cell carcinoma, vaginal, and vulvar cancers.

Other names: GI-101GI101GI 101

Targets

IL-2R (Interleukin-2/interleukin-15 receptor complex)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)

Beyond the preview

Go deeper on GI-101A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GI-101A.

Explore the full profile